TOMI Environmental gains Ireland BPR approval for SteraMist
TOMI Environmental Solutions has received formal approval in Ireland for its Binary Ionization Technology solution under the European Union's Biocidal Products Regulation, extending the Maryland-based company's authorised footprint across the bloc to 11 markets.
The approval covers BIT Solution for use with SteraMist room fogging and surface spraying equipment in professional indoor settings. Approved applications address bacteria, yeasts, and mycobacteria, targeting customers in medical, healthcare, industrial, commercial, and institutional sectors. Ireland joins Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain, and Northern Ireland on TOMI's list of EU authorisations.
Why Ireland matters
Ireland carries outsized strategic weight for any company pursuing life sciences decontamination contracts in Europe. According to IDA Ireland, the country is the world's third-largest pharmaceutical exporter and hosts more than 90 pharmaceutical companies, including nine of the top 10 global pharmaceutical firms by revenue. That concentration means contamination-control and decontamination suppliers face a demanding customer base accustomed to rigorous validation requirements under EMA and national regulatory frameworks.
TOMI chief executive Halden Shane noted that Ireland's approval reinforces SteraMist's position in "a market that is home to some of the world's most demanding contamination-control and decontamination standards." He added that rising interest from US-based customers looking to standardise decontamination protocols across multi-country operations was a contributing factor in prioritising the Irish market.
The company also acknowledged in its release that at least one established decontamination and sterilisation competitor is headquartered in Ireland, making BPR approval a necessary condition for competing on equal regulatory footing in the market.
Market context and competitive landscape
Ionised hydrogen peroxide technology sits within a broader validated decontamination segment that includes vaporised hydrogen peroxide systems, ultraviolet disinfection, and chlorine dioxide fumigation. The market has seen sustained growth since the pandemic period prompted healthcare and pharmaceutical manufacturers to strengthen environmental control programmes, and demand for multi-site, cross-border protocol standardisation has increased as large pharma groups rationalise their supplier lists.
TOMI's BIT platform, developed originally under a DARPA defence grant, positions iHP as a non-caustic, room-penetrating aerosol that can be deployed without lengthy equipment dwell times. The distinction is commercially relevant in pharma manufacturing, where production downtime is costly, though independent comparative efficacy data against incumbent vaporised hydrogen peroxide systems remains a point of scrutiny for procurement teams evaluating competing technologies.
Regulatory read-across is also worth noting: BPR authorisations are granted on a country-by-country basis within the EU mutual recognition framework, meaning each additional national approval adds direct commercial access rather than just regulatory coverage. TOMI's progression to 11 EU markets suggests a methodical regulatory expansion strategy, though the pace and cost of individual BPR submissions can constrain the rate at which smaller companies move through the remaining member states.
For investors, the Ireland approval is an incremental positive for TOMI's international commercial pipeline rather than a step-change event. The nearer-term milestones to watch are conversion of declared customer interest in Ireland into contracted revenues, and whether the company pursues further EU member-state submissions before the end of 2026.